Literature DB >> 9778055

Transgenic mouse model for skin malignant melanoma.

M Kato1, M Takahashi, A A Akhand, W Liu, Y Dai, S Shimizu, T Iwamoto, H Suzuki, I Nakashima.   

Abstract

We report here on a novel metallothionein-I (MT)/ret transgenic mouse line in which skin melanosis, benign melanocytic tumor and malignant melanoma metastasizing to distant organs develop stepwise. The process of tumor development and its malignant transformation in this line may resemble that of the human giant congenital melanocytic nevus that is present at birth and that frequently gives rise to malignant melanoma during aging. We observed an increase in the expression level and activity of the ret transgene during the disease progression. That increase in transgene expression accompanied an activation of mitogen-activated protein kinases (MAPKs) and c-Jun as well as matrix metalloproteinases. These results suggest that progressive dysregulation of the expression level of the ret transgene might play a crucial role in the malignant transformation of melanocytic tumors developed in the MT/ret transgenic mouse line.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778055     DOI: 10.1038/sj.onc.1202077

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  88 in total

Review 1.  Immune predictors of cancer progression.

Authors:  Benjamin Toh; Valerie Chew; Xilei Dai; Karen Khoo; Muly Tham; Lu-En Wai; Sandra Hubert; Sumathy Velumani; Liang Zhi; Caleb Huang; Jean-Pierre Abastado
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.

Authors:  Jo Eyles; Anne-Laure Puaux; Xiaojie Wang; Benjamin Toh; Celine Prakash; Michelle Hong; Tze Guan Tan; Lin Zheng; Lai Chun Ong; Yi Jin; Masashi Kato; Armelle Prévost-Blondel; Pierce Chow; Henry Yang; Jean-Pierre Abastado
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

3.  Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.

Authors:  M Kato; T Iwashita; K Takeda; A A Akhand; W Liu; M Yoshihara; N Asai; H Suzuki; M Takahashi; I Nakashima
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

4.  IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.

Authors:  Lloyd Bod; Renée Lengagne; Ludovic Wrobel; Jan Philipp Ramspott; Masashi Kato; Marie-Françoise Avril; Flavia Castellano; Valérie Molinier-Frenkel; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

5.  Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

Authors:  Verena von Felbert; Francisco Córdoba; Jakob Weissenberger; Claudio Vallan; Masashi Kato; Izumi Nakashima; Lasse Roger Braathen; Joachim Weis
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

6.  Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models.

Authors:  Mareike Grees; Adi Sharbi-Yunger; Christos Evangelou; Daniel Baumann; Gal Cafri; Esther Tzehoval; Stefan B Eichmüller; Rienk Offringa; Jochen Utikal; Lea Eisenbach; Viktor Umansky
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

7.  Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of γδ17 T cells in melanoma.

Authors:  Laetitia Douguet; Lloyd Bod; Renée Lengagne; Laura Labarthe; Masashi Kato; Marie-Françoise Avril; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2016-08-10       Impact factor: 8.110

8.  Tumor microenvironment and myeloid-derived suppressor cells.

Authors:  Viktor Umansky; Alexandra Sevko
Journal:  Cancer Microenviron       Date:  2012-12-16

9.  Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

Authors:  Iris Helfrich; Inka Scheffrahn; Sönke Bartling; Joachim Weis; Verena von Felbert; Mark Middleton; Masahi Kato; Süleyman Ergün; Helmut G Augustin; Dirk Schadendorf
Journal:  J Exp Med       Date:  2010-03-01       Impact factor: 14.307

10.  Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice.

Authors:  Diala El Khoury; Damien Destouches; Renée Lengagne; Bernard Krust; Yamina Hamma-Kourbali; Marylène Garcette; Sandra Niro; Masashi Kato; Jean-Paul Briand; José Courty; Ara G Hovanessian; Armelle Prévost-Blondel
Journal:  BMC Cancer       Date:  2010-06-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.